{"slideshow_credits": null, "snippet": "Purdue Pharma, the maker of OxyContin, says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, which could derail sales of the recently introduced Zohydro.", "abstract": "Purdue Pharma, maker of OxyContin, says it has completed testing of an abuse-resistant version of the painkiller hydrocodone; surprise development could derail sales of Zohydro, pain medication made by Zogenix, that has been heavily criticized for lacking such safeguards.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "THE ASSOCIATED PRESS", "original": "By THE ASSOCIATED PRESS", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/03/13/business/abuse-resistant-hydrocodone-could-sink-sales-of-new-drug.html", "lead_paragraph": "Purdue Pharma, the maker of OxyContin, says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, which could derail sales of the recently introduced Zohydro.", "headline": {"main": "Abuse-Resistant Hydrocodone Could Sink Sales of New Drug", "print_headline": "Company Says It Has Abuse-Resistant Hydrocodone", "content_kicker": "Business Briefing"}, "_id": "5320fc4338f0d80f6b2c8411", "word_count": "179", "multimedia": [], "pub_date": "2014-03-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Zogenix Inc", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Purdue Pharma", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Pain", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Pain-Relieving Drugs", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "Brief"}